https://www.selleckchem.com/pr....oducts/hydroxyfasudi
In phase 2 prospective trials using ultra APBI, encouraging results were observed regarding oncological outcome and toxicity profile. In phase 3 trials, adjuvant ET without RT significantly increased the rate of local relapse with no impact on overall survival while RT alone proved effective. Elderly patients aged 60 or more with low-risk, luminal A breast cancer were chosen as the target population in a phase 3 randomized trial comparing APBI+5-year ET vs. uAPBI (16Gy 1f) alone. To investigate de-escalation adjuvant trea
Like
Comment
Share
